Possible implication of estrogenic compounds on heart disease in menopausal women.

Autor: Lira-Silva E; Departamento de Farmacología, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano N°1, Col. Sección XVI, CP 14080 Tlalpan CDMX, Mexico., Del Valle Mondragón L; Departamento de Farmacología, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano N°1, Col. Sección XVI, CP 14080 Tlalpan CDMX, Mexico., Pérez-Torres I; Departamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano N°1, Col. Sección XVI, CP 14080 Tlalpan CDMX, Mexico., Posadas-Sánchez R; Departamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano N°1, Col. Sección XVI, CP 14080 Tlalpan CDMX, Mexico., Roldán Gómez FJ; Departamento de Consulta Externa. Instituto Nacional de Cardiología Ignacio Chávez. Juan Badiano N° 1 Col. Sección XVI Tlalpan CDMX, Mexico., Posadas-Romero C; Departamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano N°1, Col. Sección XVI, CP 14080 Tlalpan CDMX, Mexico., Vargas-Barrón J; Dirección de Investigación, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano N°1, Col. Sección XVI, CP 14080 Tlalpan CDMX, Mexico., Pavón N; Departamento de Farmacología, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano N°1, Col. Sección XVI, CP 14080 Tlalpan CDMX, Mexico. Electronic address: pavitonat@yahoo.com.mx.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Jun; Vol. 162, pp. 114649. Date of Electronic Publication: 2023 Apr 04.
DOI: 10.1016/j.biopha.2023.114649
Abstrakt: Epidemiological studies imply there is a higher risk of cardiovascular disease in menopausal women. Some explanations suggest a lack of estrogens as the cause, but estrogens do not disappear completely and are just transformed into different products called estrogenic degradation metabolites (EDMs). When estrogens are metabolized, reactive oxygen species (ROS) increase, causing DNA damage and increasing oxidative stress. These conditions are associated to neurodegenerative diseases and different types of cancer. However, their effect on the cardiovascular system remains unknown. This paper compares estrogenic metabolite levels in serum from post-menopausal women with cardiovascular risk (CAC>1) and with establish cardiovascular disease (CVD), against levels in healthy women (Ctrl). Sample sera were obtained from the Genetics of Atherosclerotic Disease (GEA) Mexican Study. Serum levels of eleven estrogenic metabolites were quantified by High performance liquid chromatography (HPLC) and oxidative stress markers such as ROS, lipoperoxidation levels (TBARS), total antioxidant capacity (TAC), super oxide dismutase activity (SOD) and cytokine levels were evaluated. 8-hydroxy-2-deoxyguanosine (8-OHdG) was also determined as a marker of nuclear damage.There were significant differences between serum levels of some EDMs in CAC> 1 and CVD vs. serum levels in Ctrl women. Results also revealed an increase in oxidative stress and a diminished capacity to manage oxidative stress. These findings provide an overview, and suggest that some estrogenic metabolites may be associated with an increased risk of CVD in menopausal women. However, additional studies are needed to evaluate the impact of these EDMs directly on cardiovascular function.
Competing Interests: Conflict of interest statement The authors declare no conflict of interest.
(Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: